Sumitomo Pharma Announces Availability of ORGOVYX® (relugolix) in Canada, the First and Only Oral Androgen Deprivation Therapy Treatment for Men with Advanced Prostate Cancer

Posted on by

MISSISSAUGA, ON, March 12, 2024 /PRNewswire/ — Sumitomo Pharma Canada, Inc., announced today that ORGOVYX® (relugolix), an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, is now available for prescription in Canada for the treatment of adult patients with advanced…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.